Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/35443
Type
ArticleCopyright
Restricted access
Embargo date
2025-01-01
Collections
- IOC - Artigos de Periódicos [12642]
Metadata
Show full item record
IMMUNE-ENDOCRINE INTERACTIONS RELATED TO A HIGH RISK OF INFECTIONS IN CHRONIC METABOLIC DISEASES: THE ROLE OF PPAR GAMMA
Doenças metabólicas crônicas
Neuroimunomodulação
Receptores ativados por proliferadores de peroxissomo
Author
Affilliation
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil / Universidade Federal do Estado do Rio de Janeiro. Instituto Biomédico. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.
Instituto de Inmunología Clínica y Experimental de Rosario (IDICER-CONICET UNR). Rosario, Argentina.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Inflamação. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil / Universidade Federal do Estado do Rio de Janeiro. Instituto Biomédico. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.
Instituto de Inmunología Clínica y Experimental de Rosario (IDICER-CONICET UNR). Rosario, Argentina.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Inflamação. Rio de Janeiro, RJ, Brasil.
Abstract
Diverse disturbances in immune-endocrine circuitries are involved in the development and aggravation of several chronic metabolic diseases (CMDs), including obesity, diabetes, and metabolic syndrome. The chronic inflammatory syndrome observed in CMDs culminates in dysregulated immune responses with low microbial killing efficiency, by means low host innate immune response, and loss of ability to eliminate the pathogens, which results in a high prevalence of infectious diseases, including pneumonia, tuberculosis, and sepsis. Herein, we review evidence pointing out PPARγ as a putative player in immune-endocrine disturbances related to increased risk of infections in CMDs. Cumulated evidence indicates that PPARγ activation modulates host cells to control inflammation during CMDs because of PPARγ agonists have anti-inflammatory and pro-resolutive properties, increasing host ability to eliminate pathogen, modulating hormone production, and restoring glucose and lipid homeostasis. As such, we propose PPARγ as a putative therapeutic adjuvant for patients with CMDs to favor a better infection control.
Keywords in Portuguese
Doenças infecciosasDoenças metabólicas crônicas
Neuroimunomodulação
Receptores ativados por proliferadores de peroxissomo
Share